Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial
Journal of the American Academy of Dermatology · 2024-12 · 91 (6) · 1113-1117
DOI: 10.1016/j.jaad.2024.08.033 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2024-12. Verfasst von Ruzeng Xue und 11 weiteren Autor:innen. Beteiligte Einrichtung: First School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Dermatology, Dermatology Hospital, Southern Medical U…. Hauptthemen laut MEDLINE: Interleukin-2, Pemphigoid, Bullous. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Regulatory T cells (Tregs) are reduced in the peripheral blood and skin lesions of patients with bullous pemphigoid (BP). Low-dose interleukin 2 (IL-2) therapy can stimulate Tregs specifically, suggesting potential for the treatment of BP. OBJECTIVE: To evaluate the response to low-dose IL-2 therapy in the treatment of moderate-to-severe BP. METHODS: Forty-three patients with moderate-to-severe BP were included. The therapy included systemic corticosteroids with an initial dose of 0.5 mg/kg/d for moderate and 1.0 mg/kg/d for severe disease, respectively, combined with allowed immunosuppressants for the control group, whereas in addition to the same corticosteroid therapy, IL-2 (half million IU) was administered subcutaneously every other day for the treatment group for 8 weeks. The primary outcome was the number of days required to achieve disease control. Secondary outcomes included other clinical responses. RESULTS: The number of days required to achieve disease control with the treatment group was (7.60 ± 3.00), which was shorter than in the control group (10.43 ± 3.06) (P = .008). The total amount of systemic corticosteroids was less, and no serious infections were detected in the treatment group. LIMITATIONS: Single center, open-label study with short duration and small size. CONCLUSION: Our trial supports the potential of low-dose IL-2 therapy for patients with moderate-to-severe BP, which showed earlier treatment responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
- Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
- Dermatology Hospital, Southern Medical University, Guangzhou, China.
- Department of Dermatology, Medical University of South Carolina, Charleston, South Carolina. Electronic address: elstond@musc.edu.
- Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China. Electronic address: yunshengliang@aliyun.com.
Zitieren
APA
Xue, R., Li, G., Zhou, Y., Wang, B., Xu, Y., Zhao, P., Teng, L., Zheng, J., Liu, H., Ji, S., Elston, D. M., & Liang, Y. (2024). Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. Journal of the American Academy of Dermatology, 91(6), 1113-1117. https://doi.org/10.1016/j.jaad.2024.08.033
Vancouver
Xue R, Li G, Zhou Y, Wang B, Xu Y, Zhao P, et al. Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. Journal of the American Academy of Dermatology. 2024;91(6):1113-1117. doi:10.1016/j.jaad.2024.08.033
BibTeX
@article{Xue2024,
author = {Xue, Ruzeng and Li, Guomin and Zhou, Yao and Wang, Bocheng and Xu, Yingping and Zhao, Peizhen and Teng, Lijun and Zheng, Jinjin and Liu, Hongfang and Ji, Suyun and Elston, Dirk M and Liang, Yunsheng},
title = {Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial},
journal = {Journal of the American Academy of Dermatology},
year = {2024},
volume = {91},
number = {6},
pages = {1113--1117},
doi = {10.1016/j.jaad.2024.08.033}
}
EUVIMED